A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646160/
https://www.ncbi.nlm.nih.gov/pubmed/23580070
http://dx.doi.org/10.1007/s10549-013-2510-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646160/
https://www.ncbi.nlm.nih.gov/pubmed/23580070
http://dx.doi.org/10.1007/s10549-013-2510-5

Ejemplares similares